CS
NKGN

Clear Street’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Clear Street’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-73,364
Closed -$609K – 964
2023
Q3 		$609K Buy
73,364
+73,242
+60,034% +$745K 0.01% 121
2023
Q2 		$1.26K Buy
+122
New +$1.25K ﹤0.01% 1033
2023
Q1 		– Sell
-700
Closed -$7K – 1285
2022
Q4 		$7K Buy
+700
New +$6.92K ﹤0.01% 589

Other funds holding NKGN

SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
UOC
University of Chicago Chicago, Illinois $323M AUM 14.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Clear Street's NKGN Position: Q4 2023 in Review

Clear Street sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q4 2023, closing a stake of 73,364 shares — an estimated $609K sold.

Clear Street first reported a position in NKGN in Q4 2022 and held it in 3 quarters. The position peaked at $609K in Q3 2023. 9 funds tracked by Wall St. Rank hold NKGN as of Q4 2023.

  • Clear Street reported no remaining NKGen Biotech, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Clear Street sold 73,364 NKGen Biotech, Inc. Common Stock shares in Q4 2023, an estimated $609K.
  • Clear Street first reported a position in NKGen Biotech, Inc. Common Stock in Q4 2022 and held it in 3 quarters.
  • Clear Street's NKGen Biotech, Inc. Common Stock position peaked at $609K in Q3 2023.
  • 9 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q4 2023.

Based on Clear Street's 13F filing for Q4 2023, filed 14 Feb 2024.